MetaCap

Fate Therapeutics (FATE) vs Voyager Therapeutics (VYGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 10.8% versus a loss of 63.4%. Over five years, VYGR leads with a -50.0% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $95.2 million), about 1.2 times the size, while Voyager Therapeutics is growing revenue faster (-49.5% vs -51.2%).

Voyager Therapeutics converts more of its revenue into profit, with a net margin of -296.5% versus -2051.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%VYGR-63.40%
+215%+69%-77%
Nov 21, 20251 yearNov 20, 2026
FATE-98.36%VYGR-53.50%
+320%+101%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus VYGR key metrics
MetricFATEVYGR
Share price$0.919$1.53
Market cap$111.82M$95.21M
1-day change-9.01%-4.97%
YTD return-6.22%-61.07%
1-year return-10.78%-63.40%
5-year return-98.25%-50.00%
EPS (TTM)$-1.03$-1.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M$40.37M
Revenue growth (YoY)-51.24%-49.53%
Net income (latest FY)$-136.31M$-119.72M
Operating margin-2222.45%-326.56%
Net margin-2051.08%-296.53%
52-week high$3.23$5.48
52-week low$0.90$1.48
Distance from 52-week high-71.55%-72.08%
Analyst consensusbuystrong_buy
Avg. price target upside+522.42%+829.41%
Average volume1.53M770.24K
Shares outstanding121.67M62.23M
Employees161141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed VYGR by 52.6 percentage points over the past year.
  • Voyager Therapeutics is more profitable, keeping -296.5 cents of every revenue dollar as net income versus -2051.1 cents for Fate Therapeutics.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About Voyager Therapeutics

VYGR stock →

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

FATE vs VYGR FAQ

Which is bigger, Fate Therapeutics or Voyager Therapeutics?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $95.21M for Voyager Therapeutics (VYGR).

Which stock has performed better over the past year, FATE or VYGR?

FATE returned -10.78% over the past 12 months, compared with -63.40% for VYGR (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and Voyager Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons